All In Biotech

Drug Trial Radar · NCT07118254

A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Sep 17, 2025

Primary completion

Mar 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Lubris Bio Pty LtdIndustry
Sponsor type
Industry
First posted
Aug 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An 84-day, prospective, randomized (1:1) vehicle controlled, double-masked pre-market, crossover study. Subjects with moderate to severe oGVHD related Dry Eye Disease Each subject will receive both treatments in random sequence, each for 28 days, separated by a 14-day vehicle washout period.

Conditions

  • Ocular Graft Versus Host Disease

Interventions

  • rhPRG4 450ug/mlDrug

    Treatment

  • Vehicle ControlDrug

    PBS Based Vehicle Control

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the efficacy of rhPRG4 using the total corneal staining with fluorescein (Oxford Scale) compared to vehicle after 28 days of treatmentTime frame: Baseline to day 28
  2. To assess the efficacy of rhPRG4 using the total VAS score (sum of dryness, foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision and photophobia, anchors: none & severe) compared to vehicle after 28 days of treatmentTime frame: From baseline to day 28

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Sydney Eye Hospital

    Sydney, New South Wales, Australia · Not yet recruiting

  • OTA

    Brisbane, Queensland, Australia · Recruiting

  • Royal Melbourne Hospital

    Melbourne, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.